Results 131 to 140 of about 228,750 (250)

Exploring Senior Emergency Physicians' Perspectives on the Inclusion of Clinical Biomarkers in Clinical Decision Rules for CT Head Use in Patients With Suspected Traumatic Brain Injury. [PDF]

Emerg Med Australas
Rogan A, Larsen P.
europepmc   +1 more source

Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials. [PDF]

Pharm Stat, 2022
Meyer EL, Mesenbrink P, Dunger-Baldauf C, Glimm E, Li Y, König F, EU-PEARL (EU Patient-cEntric clinicAl tRial pLatforms) Consortium.   +6 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Clinical Decision Rules: A Starting Place in Medical Education, Not a Destination. [PDF]

J Grad Med Educ
Woods WA, Barnes BH, Waggoner-Fountain LA.   +2 more
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Developing the Iranian health insurance benefit optimization model - the IR-HIBOM: a multicriteria decision analysis with decision rules for designing basic health insurance benefit packages. [PDF]

Int J Technol Assess Health Care
Darvishi A, Akbari Sari A, Yaseri M, Mobinizadeh M, Daroudi R.   +4 more
europepmc   +1 more source

Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists. [PDF]

Value Health, 2022
Bilinski A, MacKay E, Salomon JA, Pandya A.   +3 more
europepmc   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Study on the Diagnostic Value of Clinical Decision Rules for Malignant Tumors Complicated with Pulmonary Thromboembolism: A Retrospective Analysis. [PDF]

Clin Appl Thromb Hemost
Yang J, Wang H, Han J, Zhang L, Ma H, Liu X, Li C, Chen H, Zhang H, Fei J.   +9 more
europepmc   +1 more source